InhaTarget Therapeutics develops innovative and targeted dry powders for inhalation (DPI) that aim to improve the treatment of severe and/or chronic respiratory diseases.
InhaTarget is currently developing two anticancer DPIs to cover the gap between localized treatments (i.e. surgery and radiotherapy) and systemic treatments (i.e. conventional chemotherapies, targeted therapies and immunotherapy) in lung cancer. These innovative DPIs are at the ‘in vivo proof-of-concept’ stage.
Capitalizing on its expertise and equipment, InhaTarget Therapeutics also delivers custom inhalation product development services for pharmaceutical companies.